Ehrlichia p120/p140 Peptides for Specific Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing human monocytotropic ehrlichiosis (HME) face limitations such as lack of standardization, false positives, and cross-reactivity, making it difficult to identify the specific etiologic agent, and molecular diagnostic methods like PCR are not suitable for post-antibiotic therapy or primary care settings.
Innovation Solution
The use of p120/p140 immunoreactive peptides derived from Ehrlichia proteins for diagnosing Ehrlichia infection, which can selectively bind Ehrlichia-specific antibodies, allowing for differentiation between Ehrlichia chaffeensis and Ehrlichia canis infections, and can be used in diagnostic kits like ELISA or lateral flow assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If indirect fluorescent-antibody assay (IFA) is used for diagnosing HME, then detection capability is achieved, but standardization is lacking and false positives occur due to cross-reactivity
Solution Approach 1:
The patent segments the antigen recognition process by using synthetic peptides representing specific epitopes (e.g., TRP120-R-I1, TRP47-R+C) instead of whole-cell lysates. This segmentation allows identification of species-specific epitopes that reduce cross-reactivity while maintaining detection capability. The peptide-based approach divides the complex antigen into discrete, well-defined immunoreactive regions.
Solution Approach 2:
The patent applies local quality by focusing on specific immunoreactive regions within Ehrlichia proteins rather than using whole proteins or cell lysates. By identifying and utilizing specific epitopes (such as the tandem repeat regions of p120 and p47 proteins), the assay achieves higher species-specificity and reduces cross-reactivity with other Ehrlichia species or Anaplasma phagocytophilum.
2Measurement precision
If IFA is used for diagnosis, then Ehrlichia-specific antibodies can be detected, but expensive microscopy equipment and highly skilled technicians are required
Solution Approach 1:
The patent replaces the mechanical/optical system of fluorescence microscopy with a biochemical assay system based on peptide-antibody binding. Instead of requiring fluorescence microscopes and skilled technicians to interpret fluorescent images, the invention uses peptide antigens that can be detected through simpler readout methods, making the assay more suitable for resource-limited settings.
3Measurement precision
If PCR is used for molecular diagnosis, then specific and sensitive detection is achieved, but it is not useful after antibiotic therapy is initiated
Solution Approach 1:
The patent targets antibodies that persist longer than bacterial DNA after antibiotic treatment. By detecting antibody responses to specific peptide epitopes rather than attempting to detect residual bacterial DNA, the assay extends the diagnostic window into the convalescent phase when PCR would be negative but antibodies remain detectable.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The p120/p140 immunoreactive peptides provide improved sensitivity and specificity for diagnosing HME, comparable to the gold standard indirect fluorescent-antibody assay, and can be used for point-of-care and reference laboratory immunodiagnostics, distinguishing between active infections and immunizations.
Implementation Method 1
The p120/p140 immunoreactive peptides provide improved sensitivity and specificity for diagnosing HME... which can selectively bind Ehrlichia-specific antibodies
Data Source
Figure 1A~1B
Figure 2
Figure 3A~3B
AI summary
Provided herein are immunoreactive peptides which can selectively bind Ehrlichia-specific anti-pl20 or anti-pl40 antibodies. Methods and kits utilizing the immunoreactive peptides are also provided. The immunoreactive peptides may be utilized, e.g., for determining whether or not a subject is infected with Ehrlichia chaffeensis or Ehrlichia canis. In certain embodiments, the immunoreactive peptides may be utilized in an ELISA or lateral flow assay.